☆ 4.8 Article

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NEW ENGLAND JOURNAL OF MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Obstetrics & Gynecology

The Changing Landscape of Gynecologic Cancer Mortality in the United States

Angela N. Giaquinto et al.

OBSTETRICS AND GYNECOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin et al.

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

J. Cortes et al.

Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Dostarlimab: A Review

Barbara Costa et al.

Summary: Dostarlimab is a PD-1 monoclonal antibody approved for the treatment of endometrial cancer and has shown promising results in rectal cancer. Ongoing clinical trials are investigating its efficacy in other types of cancer. This article provides a summary of current knowledge on Dostarlimab and explores its potential as a monotherapy or in combination with other treatments.

BIOMOLECULES (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives

Damiano Arciuolo et al.

Summary: The TCGA-based molecular prognostic groups of endometrial carcinoma (EC) have improved diagnosis, risk stratification, and management. POLE-mutant and MMR-deficient groups are associated with high mutational load, morphological heterogeneity, and inflammatory infiltration. POLE-mutant ECs have good prognosis and may not require adjuvant treatment. MMR-deficient ECs have intermediate prognosis and may benefit from immunotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Review Oncology

Current Approaches to the Management of Patients with Endometrial Cancer

Emmanouil Kalampokas et al.

Summary: This review aims to evaluate and present new perspectives and ongoing developments in the management of endometrial cancer, with a focus on the application of minimally invasive surgery and Sentinel lymph node biopsy (SLNB) in treatment strategies. After reviewing literature data, it was found that minimally invasive surgery has become the preferred surgical approach, and SLNB plays an important role in the management of both low-risk and high-risk endometrial cancer.

CANCERS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine

Nathan D. Seligson et al.

Summary: Targeted therapies have revolutionized cancer treatment, with recent biomarker-driven, tissue-agnostic clinical trials marking a significant shift towards precision medicine. However, only a few tissue-agnostic indications have been approved by the FDA so far, highlighting challenges such as complex cancer biology, clinical trial design, and resistance mechanisms that future therapies targeting tissue-agnostic indications will need to overcome.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990?2019

Baoxia Gu et al.

Summary: The incidence of endometrial cancer (EC) has increased globally, while the mortality has decreased worldwide. There are significant differences between countries, and more efforts are needed to alleviate the disease burden of EC.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Uterus transplantation for fertility preservation in patients with gynecologic cancer

Pernilla Dahm-Kahler et al.

Summary: Uterus transplantation may offer hope for women with absolute uterine factor infertility caused by cervical or endometrial cancer, although it involves a complex process including careful patient and donor selection, in vitro fertilization, organ procurement surgery, and immunosuppression knowledge. Collaboration among multidisciplinary teams is crucial for successful outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

添加到收藏夹

Article Oncology

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial

Ana Oaknin et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Endometrial Cancer

Karen H. Lu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

C. Luchini et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Immunology

Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer

James W. Opzoomer et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2-A randomized phase II trial

D. Lorusso et al.

GYNECOLOGIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

Elena Fountzilas et al.

ESMO OPEN (2019)

添加到收藏夹

Article Oncology

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra et al.

BRITISH JOURNAL OF CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Does MMR status in endometrial cancer influence response to adjuvant therapy?

Soyoun Rachel Kim et al.

GYNECOLOGIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy

Giulia Viale et al.

BIOMED RESEARCH INTERNATIONAL (2017)

添加到收藏夹

Review Oncology

Microsatellite Instability as a Biomarker for PD-1 Blockade

Jonathan C. Dudley et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Oncology

The Immune Biology of Microsatellite-Unstable Cancer

Matthias Kloor et al.

TRENDS IN CANCER (2016)

添加到收藏夹

Review Oncology

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

Leisha A. Emens et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Oncology

Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

Stanleyson V. Hato et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice

Therese Liechtenstein et al.

ONCOTARGET (2014)

添加到收藏夹

Article Immunology

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

Alexandra Sevko et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Mathematical & Computational Biology

Memory and other properties of multiple test procedures generated by entangledgraphs

Willi Maurer et al.

STATISTICS IN MEDICINE (2013)

添加到收藏夹

Article Cell Biology

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice

Lukas W. Pfannenstiel et al.

CELLULAR IMMUNOLOGY (2010)

添加到收藏夹

Article Oncology

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up

B. Sorbe et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.